Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 19 April 2024, including: Teva Pharmaceutical Industries Ltd.’s immunology biosimilar launches; Intra-Cellular Therapies, Inc.’s promising depression data; Phase III sleep apnea win for Eli Lilly and Company’s tirzepatide; an interview with Viking Therapeutics, Inc.’s CEO; and China looks to define innovative drugs.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches" - Scrip, 17 April, 2024.)
(Also see "First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations" - Scrip, 17 April, 2024.)
(Also see "Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win" - Scrip, 17 April, 2024.)
(Also see "A Good Choice To Have: Scrip’s Interview With Viking CEO Brian Lian" - Scrip, 12 April, 2024.)
(Also see "Explained: How China’s Public Payer Wants To Define Innovative Drugs" - Scrip, 17 April, 2024.)
